With box warnings

Without box warnings

Branded

Generic

2 results

lucentis
(RANIBIZUMAB)
Genentech, Inc.
Usage: LUCENTIS is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
vabysmo
(Faricimab)
Genentech, Inc.
Usage: VABYSMO is indicated for treating patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It acts as a VEGF and angiopoietin 2 (Ang-2) inhibitor.

Medications for Central Retinal Vein Occlusion With Macular Edema

lucentis